KELER TIBOR has filed 3 insider transactions across 1 company since June 2023.
Most recent transaction: a grant/award of 93000 shares of Celldex Therapeutics, Inc. ($CLDX) on June 05, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 5, 2025 | Celldex Therapeutics, Inc. | $CLDX | KELER TIBOR | EXECUTIVE VP & CSO | A | Incentive Stock Option (right to buy) | 93000 | $0.00 | 93,000.0000 | 66,383 | 9999.99% | 100.00% |
| June 13, 2024 | Celldex Therapeutics, Inc. | $CLDX | KELER TIBOR | EXECUTIVE VP & CSO | A | Incentive Stock Option (right to buy) | 93000 | $0.00 | 93,000.0000 | 58,871 | 9999.99% | 100.00% |
| June 15, 2023 | Celldex Therapeutics, Inc. | $CLDX | KELER TIBOR | EXECUTIVE VP & CSO | A | Incentive Stock Option (right to buy) | 92000 | $0.00 | 92,000.0000 | 47,214 | 9999.99% | 100.00% |